Caxton Associates LLP Purchases New Stake in Pacira BioSciences, Inc. $PCRX

Key Points

• Caxton Associates LLP acquired 51,764 shares of Pacira BioSciences, valued at approximately $1.29 million, during the first quarter, holding about 0.11% of the company.
• Insider activity includes Marcelo Bigal, a director, selling 4,912 shares, resulting in a 30.13% decrease in his ownership of the stock.
• Pacira BioSciences recently reported an earnings per share (EPS) of $0.74, slightly exceeding analysts' expectations, while its stock has seen fluctuation with a current share price of $26.30.

Caxton Associates LLP purchased a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 51,764 shares of the company's stock, valued at approximately $1,286,000. Caxton Associates LLP owned 0.11% of Pacira BioSciences as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Doma Perpetual Capital Management LLC boosted its position in Pacira BioSciences by 3.2% during the 1st quarter. Doma Perpetual Capital Management LLC now owns 1,804,069 shares of the company's stock worth $44,831,000 after acquiring an additional 56,220 shares during the period. Alyeska Investment Group L.P. acquired a new position in Pacira BioSciences during the 1st quarter worth $32,506,000. Goldman Sachs Group Inc. lifted its holdings in shares of Pacira BioSciences by 49.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company's stock valued at $27,454,000 after buying an additional 367,869 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Pacira BioSciences in the fourth quarter valued at $20,266,000. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Pacira BioSciences by 88.3% during the first quarter. Jacobs Levy Equity Management Inc. now owns 855,488 shares of the company's stock worth $21,259,000 after acquiring an additional 401,227 shares during the period. Institutional investors and hedge funds own 99.73% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Wall Street Zen raised Pacira BioSciences from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Truist Financial raised Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 target price on the stock in a report on Friday, July 25th. Finally, Zacks Research raised Pacira BioSciences from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Pacira BioSciences presently has an average rating of "Moderate Buy" and a consensus price target of $30.83.

Insiders Place Their Bets

In related news, Director Marcelo Bigal sold 4,912 shares of the company's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $23.67, for a total transaction of $116,267.04. Following the transaction, the director directly owned 11,393 shares of the company's stock, valued at approximately $269,672.31. The trade was a 30.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.40% of the company's stock.

Pacira BioSciences Trading Up 0.9%

Shares of NASDAQ PCRX traded up $0.25 during mid-day trading on Monday, hitting $27.37. 269,195 shares of the company traded hands, compared to its average volume of 785,766. Pacira BioSciences, Inc. has a 1 year low of $13.04 and a 1 year high of $27.64. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -9.84 and a beta of 0.41. The company has a quick ratio of 1.91, a current ratio of 2.38 and a debt-to-equity ratio of 0.50. The business has a 50 day moving average of $24.31 and a two-hundred day moving average of $24.62.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.73 by $0.01. Pacira BioSciences had a positive return on equity of 13.29% and a negative net margin of 18.08%.The business had revenue of $181.10 million during the quarter, compared to the consensus estimate of $183.11 million. During the same period in the prior year, the business posted $0.96 earnings per share. Pacira BioSciences's revenue was up 1.7% compared to the same quarter last year. Pacira BioSciences has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current fiscal year.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.